Date | Price Target | Rating | Analyst |
---|---|---|---|
8/16/2022 | $45.00 | Buy | H.C. Wainwright |
6/16/2022 | $66.00 | Buy | ROTH Capital |
7/20/2021 | Buy | Stifel | |
7/20/2021 | $35.00 | Mkt Outperform | JMP Securities |
7/20/2021 | Outperform | Cowen & Co. | |
7/20/2021 | $35.00 | Outperform | JMP Securities |
7/20/2021 | $26.00 | Buy | Stifel |
7/20/2021 | $35.00 | Buy | Canaccord Genuity |
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
6-K - GH Research PLC (0001855129) (Filer)
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy adult subjects approved in the UK and recruitingCash, cash equivalents, other financial assets and marketable securities of $204.5 million DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter e
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway into 2026 DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter
H.C. Wainwright initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $45.00
ROTH Capital initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $66.00
Stifel initiated coverage of GH Research PLC with a rating of Buy
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million. Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million. Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million. CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The marke
HC Wainwright & Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:GHRS) with a Buy and maintains $40 price target.
Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $30 to $31.
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv
SC 13G - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)
SC 13G/A - GH Research PLC (0001855129) (Subject)